Literature DB >> 9613037

High-avidity autoantibodies to cytokines.

K Bendtzen1, M B Hansen, C Ross, M Svenson.   

Abstract

Mesh：

Substances：

Year:  1998        PMID： 9613037     DOI： 10.1016/s0167-5699(98)01252-3

Source DB:  PubMed          Journal:  Immunol Today        ISSN： 0167-5699


× No keyword cloud information.
  27 in total

1.  Neutralizing antibodies to granulocyte-macrophage colony-stimulating factor, interleukin-1alpha and interferon-alpha but not other cytokines in human immunoglobulin preparations.

Authors:  M Wadhwa; A Meager; P Dilger; C Bird; C Dolman; R G Das; R Thorpe
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

2.  Anti-interleukin 1alpha autoantibodies.

Authors:  P Miossec
Journal:  Ann Rheum Dis       Date:  2002-07       Impact factor: 19.103

Review 3.  Intravenous immunoglobulin: an update on the clinical use and mechanisms of action.

Authors:  Vir-Singh Negi; Sriramulu Elluru; Sophie Sibéril; Stéphanie Graff-Dubois; Luc Mouthon; Michel D Kazatchkine; Sébastien Lacroix-Desmazes; Jagadeesh Bayry; Srini V Kaveri
Journal:  J Clin Immunol       Date:  2007-03-11       Impact factor: 8.317

Review 4.  Antibodies as carrier proteins.

Authors:  B N Rehlaender; M J Cho
Journal:  Pharm Res       Date:  1998-11       Impact factor: 4.200

5.  Administration of intravenous immunoglobulin (IVIG) in vivo--down-regulatory effects on the IL-1 system.

Authors:  P Aukrust; F Müller; M Svenson; I Nordøy; K Bendtzen; S S Frøland
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

6.  Specificity of human anti-variable heavy (VH ) chain autoantibodies and impact on the design and clinical testing of a VH domain antibody antagonist of tumour necrosis factor-α receptor 1.

Authors:  J C Cordy; P J Morley; T J Wright; M A Birchler; A P Lewis; R Emmins; Y Z Chen; W M Powley; P J Bareille; R Wilson; J Tonkyn; A I Bayliffe; A L Lazaar
Journal:  Clin Exp Immunol       Date:  2015-09-11       Impact factor: 4.330

7.  Patients with inflammatory bowel disease may have a transforming growth factor-beta-, interleukin (IL)-2- or IL-10-deficient state induced by intrinsic neutralizing antibodies.

Authors:  E C Ebert; A Panja; K M Das; R Praveen; X Geng; C Rezac; M Bajpai
Journal:  Clin Exp Immunol       Date:  2009-01       Impact factor: 4.330

8.  Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies.

Authors:  E C Ebert; K M Das; V Mehta; C Rezac
Journal:  Clin Exp Immunol       Date:  2008-09-23       Impact factor: 4.330

9.  Granulocyte/macrophage-colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects.

Authors:  Kanji Uchida; Koh Nakata; Takuji Suzuki; Maurizio Luisetti; Masato Watanabe; Diana E Koch; Carrie A Stevens; David C Beck; Lee A Denson; Brenna C Carey; Naoto Keicho; Jeffrey P Krischer; Yoshitsugu Yamada; Bruce C Trapnell
Journal:  Blood       Date:  2009-03-12       Impact factor: 22.113

Review 10.  IgM in microbial infections: taken for granted?

Authors:  Rachael Racine; Gary M Winslow
Journal:  Immunol Lett       Date:  2009-06-17       Impact factor: 3.685
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.